REGN

Regeneron Pharmaceuticals, Inc. REGN

$676.69 -2.25 (-0.33%)

Extended · +1.46σ Grade B

+ Compare Open in Sniper

Price chart

Timeframe

Range

Loading…

Latest bar · REGN

Momentum reads · latest daily bar

Last

$676.69

-2.25 (-0.33%)

Mkt cap

$70.9B

Healthcare

RSI(14)

62.0

neutral

Stochastic %K

84.5

overbought

MFI(14)

74.7

neutral

ADX(14)

30.6

trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

Quarter	Revenue	Net income	Op income	FCF	Net margin	Op margin
2026-03-31	$3.6B	$0.7B	$0.7B	$0.8B	20.2%	20.7%
2025-12-31	$3.9B	$0.8B	$0.9B	$0.9B	21.7%	23.1%
2025-09-30	$3.8B	$1.5B	$1.1B	$1.4B	38.9%	29.6%
2025-06-30	$3.7B	$1.4B	$1.1B	$0.7B	37.9%	29.4%
2025-03-31	$3.0B	$0.8B	$0.6B	$0.8B	26.7%	19.5%
2024-12-31	$nanB	$nanB	$nanB	$nanB	nan%	nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare REGN vs peers

Line REGN up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing REGN PFE× AVGO×

Sector peers + LLY + UNH + JNJ + MRK + ABBV + TMO

Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA

Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Verdict

Weighted score 0-100 across 3 tickers · best in green

REGN

score 61.4

3/5 inputs

Perfect quality score of 100 dominates despite weak momentum of negative 9.29% over three months.

quality 100momentum 40sentiment 51

PFE

score 51.9

3/5 inputs

Maximum sentiment score of 100 driven by 16% insider buying overcomes zero quality rating.

quality 0momentum 55sentiment 100

AVGO

score 22.7

3/5 inputs

Catastrophic sentiment score of zero from negative 43% insider selling drags down otherwise neutral momentum.

quality 4momentum 54sentiment 0

Metric	REGN REGN	PFE PFE	AVGO AVGO
Snapshot
Price	676.69	25.05	370.83
Day %↕	-0.33	-0.36	-0.97
1M %↕	10.08	-3.8	-1.56
3M %↕	-9.29	-7.97	-6.94
YTD %↕	-12.83	-0.52	6.68
Market cap	—	—	—
ADV ($)	—	—	—
Beta	—	—	—
OdysseyHQ zone
Current zone	Extended	Neutral	Pullback
Dist 21-EMA %	3.74	1.53	-3.79
Dist ATR (σ)	1.46	0.7	-0.84
OdysseyHQ grade	B	—	—
Confluence↕	4	0	2
Valuation
P/E (ttm)↕	—	—	—
P/E (fwd)↕	—	—	—
P/S↕	—	—	—
EV/EBITDA↕	—	—	—
P/B↕	—	—	—
FCF yield↕	—	—	—
PEG↕	—	—	—
Growth
Revenue yoy↕	—	—	—
EPS yoy↕	—	—	—
FCF yoy↕	—	—	—
Revenue trend 8Q
Quality
Gross margin↕	—	—	—
Operating margin↕	—	—	—
Net margin↕	—	—	—
ROE↕	—	—	—
ROA↕	—	—	—
Debt / Equity↕	—	—	—
Interest cov.↕	120.42	3.82	8.08
Technicals
RSI(14)	62.0	53.6	43.8
MACD signal	bull	neutral	neutral
vs 50-DMA	4.78	-0.88	-7.97
vs 200-DMA	-3.93	-3.23	1.98
vs 52w high	-17.59	-12.87	-25.08
HV-30	27.1	23.5	66.2
Sentiment
Analyst rec↕	—	—	—
Target upside↕	—	—	—
Insider buy-sell 90d↕	-13	16	-43
Risk
Short interest↕	—	—	—
Days to cover↕	—	—	—
Next earnings	—	—	—

REGN

$676.69

-0.33%

Snapshot

Price 676.69

Day % -0.33

1M % 10.08

3M % -9.29

YTD % -12.83

Market cap —

ADV ($) —

Beta —

OdysseyHQ zone

Current zone Extended

Dist 21-EMA % 3.74

Dist ATR (σ) 1.46

OdysseyHQ grade B

Confluence 4

Valuation

P/E (ttm) —

P/E (fwd) —

P/S —

EV/EBITDA —

P/B —

FCF yield —

PEG —

Growth

Revenue yoy —

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin —

Operating margin —

Net margin —

ROE —

ROA —

Debt / Equity —

Interest cov. 120.42

Technicals

RSI(14) 62.0

MACD signal bull

vs 50-DMA 4.78

vs 200-DMA -3.93

vs 52w high -17.59

HV-30 27.1

Sentiment

Analyst rec —

Target upside —

Insider buy-sell 90d -13

Risk

Short interest —

Days to cover —

Next earnings —

Full REGN dashboard →

PFE

$25.05

-0.36%

Snapshot

Price 25.05

Day % -0.36

1M % -3.8

3M % -7.97

YTD % -0.52

Market cap —

ADV ($) —

Beta —

OdysseyHQ zone

Current zone Neutral

Dist 21-EMA % 1.53

Dist ATR (σ) 0.7

OdysseyHQ grade —

Confluence 0

Valuation

P/E (ttm) —

P/E (fwd) —

P/S —

EV/EBITDA —

P/B —

FCF yield —

PEG —

Growth

Revenue yoy —

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin —

Operating margin —

Net margin —

ROE —

ROA —

Debt / Equity —

Interest cov. 3.82

Technicals

RSI(14) 53.6

MACD signal neutral

vs 50-DMA -0.88

vs 200-DMA -3.23

vs 52w high -12.87

HV-30 23.5

Sentiment

Analyst rec —

Target upside —

Insider buy-sell 90d 16

Risk

Short interest —

Days to cover —

Next earnings —

Full PFE dashboard →

AVGO

$370.83

-0.97%

Snapshot

Price 370.83

Day % -0.97

1M % -1.56

3M % -6.94

YTD % 6.68

Market cap —

ADV ($) —

Beta —

OdysseyHQ zone

Current zone Pullback

Dist 21-EMA % -3.79

Dist ATR (σ) -0.84

OdysseyHQ grade —

Confluence 2

Valuation

P/E (ttm) —

P/E (fwd) —

P/S —

EV/EBITDA —

P/B —

FCF yield —

PEG —

Growth

Revenue yoy —

EPS yoy —

FCF yoy —

Revenue trend 8Q

Quality

Gross margin —

Operating margin —

Net margin —

ROE —

ROA —

Debt / Equity —

Interest cov. 8.08

Technicals

RSI(14) 43.8

MACD signal neutral

vs 50-DMA -7.97

vs 200-DMA 1.98

vs 52w high -25.08

HV-30 66.2

Sentiment

Analyst rec —

Target upside —

Insider buy-sell 90d -43

Risk

Short interest —

Days to cover —

Next earnings —

Full AVGO dashboard →

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

Date	EPS actual	EPS est	Surprise	Next-day
2026-04-29	9.47	8.90	+6.4%	+3.0%
2026-01-30	11.44	10.75	+6.4%	+1.8%
2025-10-28	11.83	9.64	+22.7%	-0.2%
2025-08-01	12.89	8.44	+52.7%	+2.3%
2025-04-29	8.22	8.48	-3.0%	+5.2%
2025-02-04	12.07	11.19	+7.8%	+2.8%
2024-10-31	12.46	11.70	+6.5%	+0.6%
2024-08-01	11.56	10.62	+8.8%	-1.0%
2024-05-02	9.55	10.10	-5.4%	+2.1%
2024-02-02	11.86	10.75	+10.4%	-0.9%
2023-11-02	11.59	10.78	+7.6%	-0.2%
2023-08-03	10.24	9.90	+3.5%	-0.7%
2023-05-04	10.09	9.56	+5.5%	+1.1%
2023-02-03	12.56	10.01	+25.5%	-0.3%
2022-11-03	11.14	9.48	+17.6%	+0.2%
2022-08-03	9.77	8.76	+11.6%	+1.0%
2022-05-04	11.49	9.80	+17.3%	-3.2%
2022-02-04	23.72	20.30	+16.9%	-0.1%
2021-11-04	15.37	9.94	+54.6%	-5.6%
2021-08-05	25.80	17.71	+45.7%	+1.4%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅	Mkt cap ⇅	P/E ⇅	Fwd P/E ⇅	P/S ⇅	EV/EBITDA ⇅	P/B ⇅	Gross M ⇅	Rev gr ⇅	EPS gr ⇅	FCF yld ⇅
REGN ★	$71B	16.6	12.4	4.8	14.3	2.2	43.9%	19.0%	-7.2%	4.61%
LLY	$1,051B	41.5	26.3	14.6	30.1	33.8	82.8%	55.5%	169.9%	0.87%
UNH	$387B	31.8	19.2	0.9	20.2	4.0	18.8%	2.0%	0.7%	4.57%
JNJ	$609B	29.0	19.7	6.2	18.4	7.5	68.1%	6.6%	-1.0%	—
MRK	$315B	36.0	13.2	4.8	12.1	6.9	76.7%	4.9%	—	4.46%
ABBV	$450B	124.8	15.6	7.2	17.2	-67.6	72.0%	12.4%	-46.2%	4.63%
PFE	$143B	19.1	8.8	2.3	7.6	1.6	74.8%	5.4%	-10.1%	8.67%
TMO	$198B	29.8	19.5	4.4	21.1	3.8	40.9%	6.2%	11.3%	2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 41.27%

Holder	Shares	% out
Blackrock Inc.	8,947,735	8.69%
Vanguard Capital Management LLC	6,654,913	6.46%
State Street Corporation	4,664,478	4.53%
Dodge & Cox Inc.	4,458,238	4.33%
JPMORGAN CHASE & CO	4,311,806	4.19%
Invesco Ltd.	3,905,109	3.79%
Franklin Resources, Inc.	2,722,071	2.64%
Geode Capital Management, LLC	2,607,732	2.53%
Price (T.Rowe) Associates Inc	2,177,527	2.11%
Nuveen, LLC	2,065,064	2.00%

Insider activity · 90d

0 buys / 13 sells · ratio 0.0 · Finnhub

RYAN ARTHUR F SELL 17,303 @ $650.15
RYAN ARTHUR F SELL 17,503 @ $714.13
RYAN ARTHUR F SELL 17,505 @ $712.09
RYAN ARTHUR F SELL 17,506 @ $711.49
RYAN ARTHUR F SELL 17,511 @ $710.87
RYAN ARTHUR F SELL 17,513 @ $709.45
RYAN ARTHUR F SELL 17,519 @ $707.40
RYAN ARTHUR F SELL 17,523 @ $706.74
RYAN ARTHUR F SELL 17,530 @ $705.56
RYAN ARTHUR F SELL 17,544 @ $704.28

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low

$641.0

Mean

$820.7248

High

$1000.0

Analysts

Recommendation distribution · period 2026-07-01

Revision trend (2026-04-01 → 2026-07-01): net 30 → 27 -3 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

Form	Filed	Description	Action
4	2026-07-07	PRIMARY DOCUMENT	view ·
8-K	2026-07-06	FORM 8-K	view ·
8-K	2026-06-17	FORM 8-K	view ·
13F-HR	2026-05-08	Institutional holdings (13F)	view ·
4	2026-05-04	PRIMARY DOCUMENT	view ·
10-Q	2026-04-29	10-Q	view ·
8-K	2026-04-29	8-K	view ·
DEF 14A	2026-04-24	DEFINITIVE PROXY STATEMENT	view ·
8-K	2026-04-08	FORM 8-K	view ·
4	2026-04-03	OWNERSHIP DOCUMENT	view ·
4	2026-03-03	PRIMARY DOCUMENT	view ·
4	2026-02-23	PRIMARY DOCUMENT	view ·
4	2026-02-11	PRIMARY DOCUMENT	view ·
4	2026-02-11	PRIMARY DOCUMENT	view ·
13F-HR	2026-02-06	Institutional holdings (13F)	view ·
10-K	2026-02-04	10-K	view ·
8-K	2026-01-30	8-K	view ·
8-K	2026-01-12	FORM 8-K	view ·
4	2026-01-08	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-06	PRIMARY DOCUMENT	view ·
4	2026-01-05	PRIMARY DOCUMENT	view ·
4	2026-01-05	PRIMARY DOCUMENT	view ·
4	2025-12-31	PRIMARY DOCUMENT	view ·
4	2025-12-11	PRIMARY DOCUMENT	view ·
4	2025-12-11	PRIMARY DOCUMENT	view ·
4	2025-12-11	PRIMARY DOCUMENT	view ·
4	2025-12-11	PRIMARY DOCUMENT	view ·
4	2025-12-11	PRIMARY DOCUMENT	view ·
4	2025-12-09	PRIMARY DOCUMENT	view ·
4	2025-12-09	PRIMARY DOCUMENT	view ·
4	2025-12-09	PRIMARY DOCUMENT	view ·
4	2025-12-09	PRIMARY DOCUMENT	view ·
4	2025-12-09	PRIMARY DOCUMENT	view ·
4	2025-12-09	PRIMARY DOCUMENT	view ·
4	2025-11-24	PRIMARY DOCUMENT	view ·
4	2025-11-24	PRIMARY DOCUMENT	view ·
4	2025-11-10	PRIMARY DOCUMENT	view ·
13F-HR	2025-11-07	Institutional holdings (13F)	view ·
4	2025-10-31	PRIMARY DOCUMENT	view ·
4	2025-10-31	PRIMARY DOCUMENT	view ·
10-Q	2025-10-28	10-Q	view ·
8-K	2025-10-28	8-K	view ·
8-K	2025-10-06	FORM 8-K	view ·
13F-HR	2025-08-01	Institutional holdings (13F)	view ·
10-Q	2025-08-01	10-Q	view ·
8-K	2025-08-01	8-K	view ·
8-K	2025-06-18	FORM 8-K	view ·
13F-HR	2025-05-02	Institutional holdings (13F)	view ·
10-Q	2025-04-29	10-Q	view ·
8-K	2025-04-29	8-K	view ·

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology…

Options picks · REGN

ITM + OTM ideas from the latest scan

Loading…

Congress trades · REGN

STOCK Act disclosures

Loading…

SEC filings & insiders · REGN

EDGAR · live

Loading…

Holders · REGN

Institutions & insider activity

Loading…

Regeneron Pharmaceuticals, Inc. REGN

Price chart

Latest bar · REGN

Financial overlay · last 12 quarters

Compare REGN vs peers

Earnings replay · last 20 reports

Peer comparison · Healthcare

Ownership

Top institutional holders

Insider activity · 90d

Analyst estimates

SEC filings

About REGN

Options picks · REGN

Congress trades · REGN

SEC filings & insiders · REGN

Holders · REGN

Filing summary